Beyond manufacturing capacity, sponsors seek expertise in specialized drug formulations, regulatory affairs, and service ...

Integrating best practices in AI, genomics, cell culture, and laboratory techniques together contribute to protein expression success.

With that, I will turn the call to Dr. Agafonova to provide update on our clinical development program. Nataliya? Thank you, Wa'el, and good afternoon everyone. Our stem cell therapy, Lomecel-B ...

As a result, there is a need for continued innovation and increased efficiency in terms of drug development to manage cost ... between entities. “Cell therapy research has been built on ...

Starting in 2024, all such costs have ... The CMC has to be very, very clean, because we think this is incredibly challenging. I think you all know I come from a cell therapy background, obviously ...

The experimental drug arm is compared with control arms, which may receive an active comparator (another therapy used to treat ... convenience or cost effectiveness are considered.

and AMSTERDAM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy ... and control (CMC) requirements to support its planned BLA submission. A separate Type B meeting ...

Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its breakthrough approach, Fuse Vectors aims to be the universal solution for AAV ...